Page 152 - Eceptor News Today

A recent pre-proof study published in the journal Cancer Cell assessed the CFR of cancer patients during the third wave of the coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 Omicron variant.

Researchers investigated the probability of Omicron BA.2 reinfections following SARS-CoV-2 Omicron BA.1 initial infection by whole genomic sequencing in the period of dominance of these subvariants in Denmark.

A new study examined how the quantity and quality of antibody and memory B cell responses to SARS-CoV-2 change temporally and with the number of exposures to antigens.

Researchers demonstrated that decorating the capsid surface of adenovirus vaccine vectors with a newly discovered protein superglue, DogTag/DogCatcher generates potent SARS-CoV-2-specific humoral and cellular immunity.

Researchers explore the potential of mosaic receptor-binding domain nanoparticles in protective immunity against SARS-CoV-2

A recent study investigates samples solated from unexposed individuals pre-pandemic to determine the presence of pre-existing SARS-CoV-2 B-cell immunity.

In a recent study posted to the Research Square* preprint server, which is under consideration at Scientific Reports, a team of researchers developed a novel human Alveolar Epithelial Lentivirus immortalized (hAELVi) cell infection model to estimate the replication potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses in the lower respiratory tract of humans.

The role played by the host enzyme TMPRSS2 in infection and cancer is the focus of a new study.

Researchers find that LRP1/CD91 is a leading molecule in virus-host cell interactions that causes infection by many RNA viruses.

Researchers identify 87G7, a SARS-CoV-2 neutralizing human monoclonal antibody with remarkable broad-spectrum neutralization and protection efficacy.